

Douglas R Lowy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7484889/publications.pdf>

Version: 2024-02-01

85
papers

8,293
citations

61984

43
h-index

62596

80
g-index

85
all docs

85
docs citations

85
times ranked

8482
citing authors

#	ARTICLE	IF	CITATIONS
1	Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. <i>Vaccine</i> , 2022, 40, 76-88.	3.8	15
2	Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions. <i>Journal of Virology</i> , 2022, 96, e0185721.	3.4	7
3	HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. <i>Npj Vaccines</i> , 2022, 7, 40.	6.0	1
4	Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	15
5	An Introduction to Virus Infections and Human Cancer. <i>Recent Results in Cancer Research</i> , 2021, 217, 1-11.	1.8	46
6	The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidyserine, PLCD1, and Caveolin-1. <i>Molecular Cancer</i> , 2021, 20, 141.	19.2	7
7	Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein. <i>Nature Communications</i> , 2021, 12, 6941.	12.8	5
8	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , The, 2020, 21, 1643-1652.	10.7	54
9	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. <i>New England Journal of Medicine</i> , 2020, 383, 640-649.	27.0	893
10	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	1.5	40
11	Cancer-Associated Point Mutations in the <i>DLC1</i> Tumor Suppressor and Other <i>Rho-GAPs</i> Occur Frequently and Are Associated with Decreased Function. <i>Cancer Research</i> , 2020, 80, 3568-3579.	0.9	14
12	Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1038-1046.	6.3	89
13	Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1030-1037.	6.3	42
14	DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis. <i>Oncogene</i> , 2019, 38, 7046-7059.	5.9	13
15	SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions. <i>Journal of Cell Biology</i> , 2019, 218, 3060-3076.	5.2	10
16	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. <i>Journal of Infectious Diseases</i> , 2019, 220, 1609-1619.	4.0	17
17	Human Papillomavirus 16 Capsids Mediate Nuclear Entry during Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	31
18	A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells. <i>Journal of Immunology</i> , 2019, 202, 1250-1264.	0.8	34

#	ARTICLE	IF	CITATIONS
19	Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2018, 110, 205-212.	6.3	71
20	Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression. Journal of the National Cancer Institute, 2018, 110, 390-399.	6.3	13
21	Adenovirus vectorâ€based primeâ€boost vaccination via heterologous routes induces cervicovaginal CD8⁺ T cell responses against HPV16 oncoproteins. International Journal of Cancer, 2018, 142, 1467-1479.	5.1	35
22	Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nature Communications, 2018, 9, 1960.	12.8	90
23	Human Papillomavirus Vaccines. , 2018, , 430-455.e10.		5
24	Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism. Journal of Virology, 2017, 91, .	3.4	22
25	Efficient Production of Papillomavirus Gene Delivery Vectors in Defined InÂVitro Reactions. Molecular Therapy - Methods and Clinical Development, 2017, 5, 165-179.	4.1	11
26	Preventing Cancer and Other Diseases Caused by Human Papillomavirus Infection. JAMA - Journal of the American Medical Association, 2017, 318, 901.	7.4	9
27	Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1. Journal of Cell Biology, 2017, 216, 4255-4270.	5.2	28
28	DLC1: a tumor suppressor that regulates Rho signaling. Oncotarget, 2017, 8, 27674-27675.	1.8	4
29	DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers. Oncotarget, 2016, 7, 45144-45157.	1.8	38
30	LD Motif Recognition by Talin: Structure of the Talin-DLC1 Complex. Structure, 2016, 24, 1130-1141.	3.3	68
31	Human papillomavirus capsids preferentially bind and infect tumor cells. International Journal of Cancer, 2016, 138, 901-911.	5.1	35
32	A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging. Journal of Virology, 2016, 90, 1096-1107.	3.4	14
33	Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute, 2016, 108, djv302.	6.3	92
34	HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. Journal of Clinical Investigation, 2016, 126, 5-11.	8.2	65
35	Reply to Nalin. Journal of Infectious Diseases, 2015, 212, 2021.2-2022.	4.0	0
36	Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 74-89.	4.5	14

#	ARTICLE	IF	CITATIONS
37	The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane. <i>Virology</i> , 2015, 481, 79-94.	2.4	11
38	Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. <i>Lancet Oncology</i> , The, 2015, 16, e226-e233.	10.7	66
39	Topical Herpes Simplex Virus 2 (HSV-2) Vaccination with Human Papillomavirus Vectors Expressing gB/gD Ectodomains Induces Genital-Tissue-Resident Memory CD8 ⁺ T Cells and Reduces Genital Disease and Viral Shedding after HSV-2 Challenge. <i>Journal of Virology</i> , 2015, 89, 83-96.	3.4	36
40	Raising Expectations For Subunit Vaccine. <i>Journal of Infectious Diseases</i> , 2015, 211, 1373-1375.	4.0	74
41	The Cdk5 activator P39 specifically links muskelin to myosin II and regulates stress fiber formation and actin organization in lens. <i>Experimental Cell Research</i> , 2015, 330, 186-198.	2.6	15
42	Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2965-2974.	3.3	7
43	Maturation of the Human Papillomavirus 16 Capsid. <i>MBio</i> , 2014, 5, e01104-14.	4.1	64
44	Strain-Specific Properties and T Cells Regulate the Susceptibility to Papilloma Induction by <i>Mus musculus</i> Papillomavirus 1. <i>PLoS Pathogens</i> , 2014, 10, e1004314.	4.7	59
45	Antibody to the gp120 V1/V2 Loops and CD4 ⁺ and CD8 ⁺ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. <i>Journal of Immunology</i> , 2014, 193, 6172-6183.	0.8	34
46	CDK5 is a major regulator of the tumor suppressor DLC1. <i>Journal of Cell Biology</i> , 2014, 207, 627-642.	5.2	46
47	Human papillomavirus vaccines. , 2013, , 235-256.		5
48	Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1399-1406.	3.3	35
49	Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. <i>Cancer Prevention Research</i> , 2013, 6, 1242-1250.	1.5	185
50	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. <i>PLoS ONE</i> , 2013, 8, e68329.	2.5	387
51	Isolation of Mouse Embryo Fibroblasts. <i>Bio-protocol</i> , 2013, 3, .	0.4	123
52	Functional Interaction of Tumor Suppressor DLC1 and Caveolin-1 in Cancer Cells. <i>Cancer Research</i> , 2012, 72, 4405-4416.	0.9	42
53	Inactivation of the <i>Dlc1</i> Gene Cooperates with Downregulation of <i>p15INK4b</i> and <i>p16Ink4a</i> , Leading to Neoplastic Transformation and Poor Prognosis in Human Cancer. <i>Cancer Research</i> , 2012, 72, 5900-5911.	0.9	27
54	Reducing HPV-Associated Cancer Globally. <i>Cancer Prevention Research</i> , 2012, 5, 18-23.	1.5	184

#	ARTICLE	IF	CITATIONS
55	Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®. <i>Vaccine</i> , 2012, 31, 165-170.	3.8	48
56	Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. <i>Vaccine</i> , 2012, 30, 6016-6019.	3.8	162
57	Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1444-1451.	6.3	274
58	Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17129-17134.	7.1	95
59	Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. <i>Cancer Discovery</i> , 2011, 1, 408-419.	9.4	143
60	Prognostic Implications of HPV in Oropharyngeal Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 82-84.	27.0	54
61	Vaccines to Prevent Infections by Oncoviruses. <i>Annual Review of Microbiology</i> , 2010, 64, 23-41.	7.3	88
62	In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection. <i>Cell Host and Microbe</i> , 2010, 8, 260-270.	11.0	148
63	The Tensin-3 Protein, Including its SH2 Domain, Is Phosphorylated by Src and Contributes to Tumorigenesis and Metastasis. <i>Cancer Cell</i> , 2009, 16, 246-258.	16.8	81
64	Human papillomavirus infection and the primary and secondary prevention of cervical cancer. <i>Cancer</i> , 2008, 113, 1980-1993.	4.1	121
65	HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. <i>Cancer</i> , 2008, 113, 3036-3046.	4.1	438
66	Human papillomavirus, cervical cancer prevention, and more. <i>Vaccine</i> , 2008, 26, iii-iv.	3.8	11
67	Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 9012-9017.	7.1	174
68	Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 743.	7.4	581
69	DLC1: a Rho GTPase-activating protein and tumour suppressor. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1185-1207.	3.6	175
70	Prophylactic human papillomavirus vaccines. <i>Journal of Clinical Investigation</i> , 2006, 116, 1167-1173.	8.2	312
71	Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. <i>Virology</i> , 2005, 337, 365-372.	2.4	158
72	Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. <i>Vaccine</i> , 2005, 23, 3634-3641.	3.8	93

#	ARTICLE	IF	CITATIONS
73	Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genetics, 2005, preprint, e214.	3.5	0
74	Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology, 2004, 321, 205-216.	2.4	325
75	Chapter 16: Prophylactic Human Papillomavirus Vaccines. Journal of the National Cancer Institute Monographs, 2003, 2003, 111-116.	2.1	54
76	Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing Epitopes. Virology, 2000, 270, 254-257.	2.4	222
77	Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations. , 1996, 68, 704-709.		34
78	Rational cancer therapy. Nature Medicine, 1995, 1, 747-748.	30.7	8
79	Cell Transformation by <i>ras</i> and Regulation of its Protein Product. Novartis Foundation Symposium, 1993, 176, 67-84.	1.1	6
80	Suppression of c-ras transformation by GTPase-activating protein. Nature, 1990, 346, 754-756.	27.8	169
81	Retroviruses expressing different levels of the normal epidermal growth factor receptor: Biological properties and new bioassay. Journal of Cellular Biochemistry, 1989, 39, 153-166.	2.6	60
82	New clue to Ras lipid glue. Nature, 1989, 341, 384-385.	27.8	76
83	Adenylate cyclase activity of NIH 3T3 cells morphologically transformed by ras genes. FEBS Letters, 1986, 197, 134-138.	2.8	32
84	An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature, 1986, 323, 822-824.	27.8	218
85	The p21 ras C-terminus is required for transformation and membrane association. Nature, 1984, 310, 583-586.	27.8	586